[Edaily] February 1, 2018
Miracell in final stages of anticancer efficacy testing
Miracell, a stem cell specialist, has recently begun anticancer efficacy testing using blood-derived immune cells and stem cells, bringing the development of a treatment closer to reality.
Miracell is currently using its proprietary cell separation and concentration technology to rapidly isolate immune cells and stem cells from blood,
and is conducting analysis of their anticancer effects on colon cancer cells.
A Miracell representative stated on the 1st, “This anticancer cell therapy candidate is demonstrating exceptional anticancer efficacy.”
They added, “In particular, the treatment preparation period is much shorter than existing products, so we anticipate more efficient application in the future.”
Miracell, a company approved for cartilage regeneration, lower extremity ischemia, and myocardial infarction,
is currently developing a minimally invasive source technology that can be easily processed in-hospital, targeting general hospitals, semi-general hospitals, and clinics.
This technology has already signed contracts with several Southeast Asian countries and is preparing for export. Miracell is also developing stem cell culture cosmetics, which are receiving rave reviews.
Miracell’s stock is currently traded on the over-the-counter market.
Shin Hyun-soon, Co-CEO of Miracell, stated, “We are confident that the cell therapy products we are developing will establish themselves as a new growth engine through overseas exports.”
Cell therapy products are pharmaceuticals used for therapeutic, diagnostic, and preventive purposes. They involve a series of procedures, such as ex vivo proliferation, selection, or other modification of the biological properties of living autologous, allogenic, or xenogenic cells, to restore cell and tissue function.
Cell therapy products can be categorized into somatic cell therapy and stem cell therapy, depending on the type and level of differentiation of the cells used.
Stem cell therapy products are further categorized into embryonic stem cell therapy and adult stem cell therapy.
Medical institutions are permitted to process autologous or allogeneic cells during surgery or other procedures, provided that minimal manipulation (such as simple separation, washing, freezing, or thawing, as long as biological properties are maintained) is performed without safety concerns.
(Article 2, Paragraph 14 of the Regulations on Approval and Review of Biochemical Products, etc.)
Furthermore, among cell therapy products deemed safe, processing within medical institutions is considered minimal manipulation. Miracell, which has received approval to do so, has created a stir in the medical community.
Lee Soon-yong, Edaily